Figure 1From: Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece Cost effectiveness acceptability curves of liraglutide vs. sitagliptin (red line) and liraglutide vs. exenatide (blue line). Back to article page